A US healthcare company operating a large network of acute-care and specialty hospitals across dozens of states, plus hundreds of ambulatory surgery centers run through its USPI arm. It also owns Conifer Health Solutions, which handles medical billing and revenue-cycle services for hundreds of outside clients. Tenet was born in 1995 when two major hospital chains, National Medical Enterprises and American Medical International, merged and adopted a name drawn from the word "tenet" — a core belief or principle.
A $413M contract termination payment drove operating income up 82%, overshadowing a 1.2% decline in Ambulatory Care same-facility cases.
A one-time contract termination payment reshaped the quarter. rose 6.8% to $5.6 billion and climbed 82% to $1.5 billion, but the increase was driven by a $413 million gain from ending a Conifer-CommonSpirit Health agreement, not by a step-change in core operations. The underlying business showed mixed signals: hospital volumes grew while Ambulatory Care same-facility cases fell 1.2%.
Key takeaways
rose 82.4% to $1.501 billion, but the increase was driven by a $413 million gain from the termination of a revenue cycle management agreement with CommonSpirit Health.
Ambulatory Care grew 9.3% to $1.27 billion, but declined 1.2%, with revenue growth coming from higher commercial rates, patient acuity, and new service lines.
Hospital Operations same-hospital net operating revenues rose on higher patient volumes, and same-hospital salaries, wages and benefits as a percentage of net improved 170 to 44.7%.
Section summaries
Management's Discussion and Analysis
Q2 2026 revenue rose 6.8% to $5.6B driven by higher patient volumes and Ambulatory Care growth, while operating income surged 82% aided by a $413M contract termination payment.
⌄
Consolidated net operating revenues increased 6.8% to $5.628 billion, with Hospital Operations up 6.0% on higher volumes and Ambulatory Care up 9.3% from acquisitions and same-facility growth.
fell 37.5% to $585 million, as the prior-year quarter included $342 million in advances from managed care payers following a claims clearinghouse cyberattack.
The company repurchased 5.675 million shares for $1.042 billion in Q2 2026, a pace that consumed most of the remaining authorization.
Management warned that the expiration of enhanced Affordable Care Act subsidies and the future implementation of the One Big Beautiful Bill Act could materially reduce insurance coverage and government payments.
What changed
The Q2 2025 filing flagged whether Ambulatory Care organic case growth would return; in Q2 2026, same-facility cases fell 1.2%, meaning growth remained dependent on rate increases and newly acquired facilities.
The Q2 2025 filing flagged whether the expiration of enhanced ACA subsidies would pressure the payer mix; in Q2 2026, management explicitly warned that the expiration and the One Big Beautiful Bill Act could materially reduce insurance coverage and government payments.
The Q1 2026 filing flagged whether the 0.1% same-hospital growth and the 1.5% decline in represented a new baseline; Q2 2026 showed a return to volume-driven hospital revenue growth, though the payer mix question remains open.
The Q1 2026 filing flagged whether the $549 million spent to acquire Conifer's noncontrolling interests signaled a shift in capital allocation; Q2 2026 saw $1.042 billion in share repurchases, indicating buybacks remain the primary use of capital.
What to watch
Whether Ambulatory Care same-facility case volumes return to growth in Q3 2026 after the 1.2% decline in Q2, or whether the 's growth remains dependent on rate increases and acquisitions.
Whether the expiration of enhanced Affordable Care Act subsidies shifts patients from commercial to government coverage, pressuring the favorable payer mix that has supported same-hospital growth.
The pace of share repurchases against the remaining authorization after $1.042 billion was spent in Q2 2026, and whether the company continues to prioritize buybacks over debt reduction or Ambulatory Care acquisitions.
The outcome of the DOJ civil investigative demand issued to Detroit Medical Center, which remains unresolved and could still result in a material settlement or penalty.
more than doubled to $1.501 billion, primarily due to a $413 million recognition from the termination of a revenue cycle management agreement with CommonSpirit Health.
Same-hospital salaries, wages and benefits as a percentage of net improved 170 to 44.7%, driven by volume and lower health benefits costs.
Ambulatory Care same-facility systemwide net grew 5.0% despite a 1.2% case decline, reflecting higher commercial rates, patient acuity, and new service lines.
Net was $2.226 billion for the first half of 2026, boosted by $540 million in contract termination payments, while $1.042 billion was used to 5.675 million shares in Q2.
Management warns that the expiration of enhanced Affordable Care Act subsidies and the future implementation of the One Big Beautiful Bill Act could materially reduce insurance coverage and government payments.
Quantitative and Qualitative Disclosures About Market Risk
The following table presents information about certain of our market-sensitive financial instruments at June 30, 2026. The fair values were determined based on quoted market prices for the same or similar instruments. The average effective interest rates presented are based on t…
⌄
The following table presents information about certain of our market-sensitive financial instruments at June 30, 2026. The fair values were determined based on quoted market prices for the same or similar instruments. The average effective interest rates presented are based on the rate in effect at the end of the reporting period. The effects of unamortized discounts and issue costs are excluded from the table.
Maturity Date, Years Ending December 31,
2026 2027 2028 2029 2030 Thereafter Total Fair Value
(Dollars in Millions)
Fixed-rate long-term debt $ 45 $ 1,643 $ 2,422 $ 1,457 $ 3,488 $ 4,278 $ 13,333 $ 13,224
Average effective interest rates 7.5 % 5.4 % 5.8 % 4.4 % 5.4 % 6.3 % 5.7 %
We have no affiliation with partnerships, trusts or other entities (sometimes referred to as “special-purpose” or “variable-interest” entities) whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements by us. As a result, we have no exposure to the financing, liquidity, market or credit risks associated with such entities. We do not hold or issue derivative instruments for trading purposes and are not a party to any instruments with leverage or prepayment features.
Because we provide healthcare services in a highly regulated industry, we have been and expect to continue to be party to various lawsuits, claims and regulatory investigations from time to time. For information regarding material legal proceedings in which we are involved, see…
⌄
Because we provide healthcare services in a highly regulated industry, we have been and expect to continue to be party to various lawsuits, claims and regulatory investigations from time to time. For information regarding material legal proceedings in which we are involved, see Note 11 to our accompanying Condensed Consolidated Financial Statements, which is incorporated by reference.